The novel drug-eluting contact lens is a great substitute for traditional eye drops, which are plagued by problems, such as low drug administration efficiency, discomfort,repeated dosing. Drugs can stay on the eyeball for a sufficient period of time. Patients can have access to treatment in an appropriate state at any time. With these advantages, the novel drug-eluting contact lens is expected to become a new method for the treatment of ophthalmic diseasesfor the recovery of patients after ophthalmic surgery. It has broad application prospects in the treatment of ophthalmic diseases.

BPRSJ338 exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19 as a first-in-class drug. BPRSJ338 also potently inhibits against broad-spectrum coronaviruses including SARS-CoV-2, SARS-CoV, HCoV-229E, HCoV-OC43, TGEV, FIPV and MHV. Related US and Taiwan patents have been granted.​ Therefore it is also applicable to fight against severe evolving coronaviruses in the future.

Chronic wound infection is a leading cause of mortality in injured patients worldwide. At present, available systemic antibiotic treatments have an insufficient tissue penetration ability and allow the development of antibiotic-resistant pathogens. The identification of therapeutic agents with wound healing and antimicrobial functions is necessary to heal the wound and cure infections. Our report shows that the antimicrobial peptide (AMP) Epinecidin-1 (Epi-1) efficiently heals MRSA-infected heat burn injuries and provides protection from infection in mouse and pig model. Our results demonstrate that the biomaterial Epi-1 heals wounds through increasing epithelial cell proliferation, vascularization, and the formation of collagen and controls MRSA infection-mediated sepsis in pigs.

The present invention discloses the germplasm bank of medicinal coral producing new targeted anti-cancer agent and their aquaculture technology platform. The medicinal corals are collected in Kenting, located at the southern tip of Taiwan. In response to the unmet medical needs of new anti-cancer drugs, our research results will provide more diverse types of new drug targets and lead compounds in the "new drug development-new drug discovery and exploration period".

This invention is to apply PS1 to treatreverse T2D. The invention can be developed into small-molecule drugs. Those are first-in-class drugs for T2D because its novel anti-diabetic mode of action.

Through combining the cutting-edge technology of TD-ESI/MS to its comprehensive database library of toxicants, a fast-track toxicant analytical platforma set of standard operating procedures are developed that enables the emergency physicians to access correct toxicological information within a short turnaround timerescue the poisoned patients based on accurate laboratory data.

"1. New method to prepare (3S, 3’S)astaxanthin, with high yield, high stabilityharmless to organism 2. The method has variety of biological activities anti-oxidation, anti-agingpromote damage tissue repair 3. It has anti-cancer potential, especially effective against metastatic cancer cells 4. Applied as Multifunctional medical supplies, functional foods, functional drinks, cosmeticsmaintenance products"

These stimuli-switchable nanoparticles coated with the cleavable outer polymer coatingmultifunctional peptides may afford a new platform for anticancer drugmiR. These nanoparticles possess characteristics of environmental response, active targeting,gene/chemo combinatorial therapeutics, thus providing spatiotemporal control of posttranｓｃｒｉｐｔional gene regulation, smart nuclear/mitochondrial localization,simultaneous inhibition of multiple progression pathways of tumor cells for enhancing antitumor efficacysafety of cancer therapy.

We have developed an innovative acoustic vortex technology VorteSonic for treatment of VTE, with the first go-to-market product of a catheter-based acoustic vortex thrombolytic device. Acoustic vortex produces turbulent flow around the thrombus, resulting in effective thrombolysis by creating loose structure of thrombustherefore enhancing deep penetration of thrombolytic drugs into the thrombus. Advantages of the acoustic vortex technology is reduction of hemorrhagic riskimprovement of safetyprognosis. Feedback system can be integrated for intelligent therapy in the future.

This technology is mainly solved the side effects of anti-obesity drug, including soft stoolsoily stools,regulate oil absorptionmetabolism as an additive in food. During the experiment, the curing phenomenon of MSNs/oiloily stool reduction in animal were observed. In conclusion, MSNs can effectively reduce the side effects of Orlistatelevating life quality.

This technology is a development drug lead aiming to meet the medical needs of patients with small cell lung cancer. Through disturbing MYC-Aurora A interaction and inducing degradation of MYC oncoprotein, this bioavailable kinase inhibitor could serve as a potential treatment entity for SCLC.

X-ray diffraction technology is used to analyze the drug efflux pump, ST50, form S. Typhi. The drug efflux mechanism for multiple drug resistant (MDR) S. Typhithe potential location for antigen of market-based typhoid detection reagent are understood through this ST50 structure. It could help develop the more effective typhoid detection reagentthe new antibiotics against MDR S. Typhi.

Diabetes is now still an incurable disease. Beta cell failure is one of common causes. No drugs for this failure have been developed. This invention is to developapply PS1 to treatreverse diabetes. PS1 is a first-in-class small-molecule drug, which targets beta cells by improving their survivalfunction. As a result, PS1 can treatreverse diabetes. The anti-diabetic mechanism of

We propose an AI dynamics drug repurposing platform applicate on COVID-19. This platform analyzed a large number of structures of SARS-CoV, MERS,cross-species coronavirus 3CL protease-ligand complexes to construct uncovering six flexible active site conformationspharmacophore clusters for SARS-CoV-2 3CL protease screening all FDA drugsfound four inhibitors within three months. Among them, JM206 had even demonstrated ten times better efficacy than Remdesivir in-vitro assayalso show the effect on the in-vivo hamster model to alleviate the symptoms caused by COVID-19.

The key technology of Patient Derived Tumor Spheroids (PDTS) is to create an in-vitro patient tumor microenvironmenttumor-like properties, furthermore, predict various cancer antidrug effectiveness to each patient via the high-throughputhigh-quality cell viability detectionbiomarker analysis. Therefore, this project established several technologies including extracellular matrix fabrication, bioink design, cell population identification,tumor physiological environment for the upon goal.

Our inter-institutional research team developed RS-D7, a novel NMDAR modulator/DAO inhibitor as a drug candidate for the treatment of ataxia/MSA. Based upon the core symptoms, we designedapplied preclinical mouse behavioral phenotyping techniquesclinical motor assessments to demonstrate the effectiveness of RS-D7our functional assays. RS-D7 offers multi-symptomatic relief.

By the help of the High Throughput Core Facility of the Genome Center of the Academia Sinica, potential drugs with activity are screened out,the P3 laboratory conducts the antiviral cell experiment of the drug to accurately determine the effect of inhibiting the virus. In addition, the production process of the antiviral drug "Remdesivir" is improved,innovative preparation methods are proposed, which greatly increase the yield of "Remdesivir"effectively reduce the manufacturing cost.

We used the concepts of tissue regeneration, embedding drugs in biomaterial carriers,a rigorous regeneration deficient animal model with severe hind limb ischemia to develop an effective novel therapy Grace-001. The new drug can promote neovascularization, tissue regeneration, blood flow maintenance,restoration of blood vessels, nerves,muscles as well as their functions. This new dr

Our present invention firstly provides a new ultrasound (US)-multifunctional microbubble (MB) which can be applied to a topical region of the body surface of organisms by applyingsputtering, instead of using injection. Some interesting topics have been explored: 1. US-aided MBs facilitate the delivery of drugs to the inner ear via the transcanal method, 2. drug-carrying modified MB combine wit

"Establish an immunological-based platform for nano drug: 1. Establish macrophages as an in vitro cell-based testing platform 2. Safety assessmentimmunomodulatory effects of nano drugs 3. Gold nanodots as a specific target of Nrf2 pathway against chronic diseases."

Due to the recent outbreak of COVID-19ongoing mutants, we developed a coronavirus variant protein microarray that includes all the current spike mutationsthe wild-type viral antigensapplied in detecting immune responsesdrug specificities. We filed the patientspublished our findings in the Analytical Chemistry. Besides massive production of the coronavirus protein microarray, we also collaborated with a scanner company, developed artificial intelligence software,collaborated with suppliers. We are welcome any sort of collaboration.

Our core generated several types of transgenic micea stable humanized ACE2 mice using a combi-CRISPR genetic engineering technique. We hope these mouse models can help to dissect COVID-19 pathogenic mechanismthe interaction(s) between spike proteinACE2 K353.

This project will establish a National biobank consortium of Taiwan (NBCT) through the fund supportgovernance from the government. All Alliance will follow the same SOP for the biomaterial collectionhave the same quality of the biosample. Adequateconsistent clinical data will also be established under well information security management. Since the contents of the biobanks from different institute are quite different, we will be able to quickly establish a largecomprehensive biobank network. In line with the needs of biotechnology pharmaceutical, artificial intelligence, auxiliary medicalother industries.

Current mainstream pharmacotherapy of glaucoma is the delivery of intraocular pressure-lowering medication via topical instillation. But, this dosage form has practical limitations due to well-known ocular barriers to drug transport. For the first time, highly efficient compound eye drop formulation is designed based on the idea of innovative glutathione-functionalized gelling materials. Our biomaterials-based ophthalmic drops can better improve drug bioavailabilityantiglaucoma efficacy than currently marketed eye drops, thereby showing future clinical translational potential.

Ninety percent of human diseases are related to abnormal inflammation. WJM team has successfully developed a new monoclonal antibody that can inhibit a key inflammation protein. Animal experiments have accumulated more than ten disease modes, including a variety of solid tumors, fibrosis, degenerativecardiovascular diseases. This antibody is qualified as an orphan drug for the treatment of IPF. New coronary pneumonia has greatly increased the demand for pulmonary fibrosis treatment,has also become an important target for mergersacquisitions of global pharmaceutical companies.

Our team has developed technology to build lung-on-a-chip with the aim of creating alternatives for animal researchachieving more accuratereliable preclinical experimental data.The chip＇s rapideffective screening ability will help the clinical community to reduce costsdrastically shorten the drug-development process.

Lung-on-minilab is designed as a tool for personalized healthcarewill contribute in precision medicine. Here, the tumor microenvironment was reconstituted using liquid dielectrophoresisarranged as lung tissue. The size of pattern can be customized as stages of cancer. Additionally, this chip was equipped a gradient microfluidic channel which enabled testing combination of medications. This is the first device where chemotherapyimmunotherapy medications can be tested together. This will improve the screening timeserve as an alternative for patients in therapeutic try.

Our solution is able to noninvasively reconstruct 3D skin microstructuremicroangiography with micrometer-scale resolutions for diagnoses of skin disorders. Moreover, various skin parameters can be quantitatively evaluated from 3D images according to the proposed algorithms, including the thickness of stratum corneum, the thickness of epidermis, water concentration, collagen concentration,skin roughness. The developed technique can be applied to different clinical environments including hospitalscosmetic clinics for diagnosesanalyses of skin.

Surface-enhanced Raman spectroscopy (SERS) is a useful analytical technique for detecting extremely small amounts of molecules. Herein, we designed a paper-based quasi-three-dimensional SERS substrate (P-SERS) that can provide potential to improve Raman analyses for food safety, pesticide poisoning, precision medicine, drug abuse and DNA/RNA testing. The sensitive, low-cost, flexible and disposable SERS substrate could be easily fabricated by physical deposition of gold nanoparticles array onto a filter paper. In this case, we are able to create non-continuous Au islands on the fiber surfaces, where the gaps between AuNPs can dramatically generate the high electric field to enhance Raman signal of target molecules.

An international collaboration led by Prof. Lih-Chu Chiou, College of Medicine, National Taiwan University, has identified a novel promising drug candidate, the α6-containing GABAA receptor-selective positive allosteric modulator, for the treatment of migraine, trigeminal painneuropsychiatric disorders (schizophreniaTourette syndrome).